AlloVir stockholder vote approves doubling authorized common shares to 300M

Kalaris Therapeutics, Inc.

Charter amendment filed May 15 increases authorized common from 150M to 300M shares.
Proposal 3 approved: 86,571,410 for, 544,049 against, 1,225 abstain.
Class III directors elected: Bornstein, Brainard, Hallal, Tomasello; vote totals provided.
Ratification of Deloitte & Touche as auditor for FY2023 approved: 86,411,460 for.
Record date March 15, 2023; 93,511,558 shares outstanding and entitled to vote.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kalaris Therapeutics, Inc.: Increased authorized shares of common stock from 150,000,000 to 300,000,000 (effective 2023-05-15).

Change: charter amendment
Effective: 2023-05-15

Exact text from the filing

On May 15, 2023, AlloVir, Inc. (the “Company”) filed a certificate of amendment to its amended and restated certificate of incorporation (the “Charter Amendment”) with the Secretary of State of the State of Delaware to increase the authorized shares of common stock from 150,000,000 to 300,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kalaris Therapeutics, Inc. shareholders approved Election of Class III directors: Jeffrey Bornstein, Diana Brainard, M.D., David Hallal, Shawn Tomasello at the 2023-05-11 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-11

Exact text from the filing

The Company’s stockholders approved the Class III director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Class III Director Nominee For Withhold Broker Non- Votes Jeffrey Bornstein 51,184,647 11,888,021 24,044,016 Diana Brainard, M.D. 54,972,729 8,099,939 24,044,016 David Hallal 54,298,062 8,774,606 24,044,016 Shawn Tomasello 51,020,208 12,052,460 24,044,016

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kalaris Therapeutics, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized common shares from 150,000,000 to 300,000,000 at the 2023-05-11 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-05-11

Exact text from the filing

For Against Abstain 86,571,410 544,049 1,225

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Kalaris Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-11 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-11

Exact text from the filing

For Against Abstain 86,411,460 689,359 15,865

View on SEC.gov

102 governance changes filed in the last 30 days. Browse all governance changes →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-146091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.